Deep dives for pharma professionals
Research, innovation and market-trend explainers — the context behind the headlines, written for people who work in the industry.
How Geopolitical Risks Are Reshaping API Supply Chains
Market TrendsCapital Investments In Next-Generation Facilities Explained
Capital Investments In Next-Generation Facilities are turning pharma manufacturing into a top strategic priority, not a background function.
InnovationGenomic Sequencing For Contamination Investigations Explained
Genomic sequencing reads a pathogen's exact genetic fingerprint. Here's how it traces contamination to its source faster than ever before.
InnovationIsolator and RABS adoption curves in sterile fill-finish
Annex 1 is reshaping barrier technology choices, here's where isolator and RABS adoption stands, and why isolators are pulling ahead.
Continued Process Verification In Pharma: What Literature Shows
CPV theory is well understood, but literature shows execution is uneven, here's what real-world data reveals about running Stage 3 well.
How to Minimize Patent Rejection Setbacks with Access to Comprehensive Information
Patent rejections are costly and common, here's how proactive prior art searches and expert IP guidance help companies file stronger, faster.
Market TrendsUS Tariff Exposure By Manufacturing Footprint: A Sector Map
Learn how US pharmaceutical tariffs affect pharma manufacturers based on their manufacturing footprint, including India, APIs, generics, and onshoring.
Market TrendsCDMO Trends 2026: What’s Driving Mergers And Acquisitions
CDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.
Why Investment In Advanced Therapy Manufacturing Matters
Advanced therapy manufacturing is struggling to keep pace with cell and gene therapy breakthroughs, and the funding gap now decides patient access.
Why GLP-1 Manufacturing Capacity Is Biggest Bottleneck in Pharma
A practical look at where GLP-1 manufacturing capacity stands today, and how Novo Nordisk, Lilly, and a growing CDMO network are closing the supply gap.
Recombinant Endotoxin Testing: What the Evidence Actually Shows
A research summary on rFC and rCR reagents, regulatory status, and validation data,what the evidence actually shows on recombinant endotoxin testing.
Market TrendsCDMO Consolidation Trends 2026: Mergers & Acquisitions
CDMO trends 2026 show a structural consolidation wave, bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.